KALV

$0.00

(

0.00%

)
Quote details

stock

Kalvista Pharmaceuticals Inc

NASDAQ | KALV

11.07

USD

$0.00

(

0.00%

)

At Close (As of Oct 16, 2025)

$603.25M

Market Cap

-

P/E Ratio

-3.94

EPS

$17.28

52 Week High

$7.30

52 Week Low

HEALTHCARE

Sector

KALV Chart

Recent Chart
Price Action

KALV Technicals

Tags:

KALV Earnings

Yearly Income Statement (As of Apr 30, 2025)

Field Value (USD)
Gross Profit -$941K
Total Revenue $0
Cost Of Revenue $941K
Costof Goods And Services Sold $941K
Operating Income -$188M
Selling General And Administrative $116M
Research And Development $72M
Operating Expenses $188M
Investment Income Net -
Net Interest Income $650K
Interest Income $6.4M
Interest Expense $5.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $941K
Income Before Tax -$180M
Income Tax Expense $3.4M
Interest And Debt Expense -
Net Income From Continuing Operations -$183M
Comprehensive Income Net Of Tax -
Ebit -$174M
Ebitda -$173M
Net Income -$183M

Revenue & Profitability

Earnings Performance

KALV Financials

yearly Balance Sheet (As of Apr 30, 2025)

Field Value (USD)
Total Assets $251M
Total Current Assets $242M
Cash And Cash Equivalents At Carrying Value $99M
Cash And Short Term Investments $99M
Inventory -
Current Net Receivables $15M
Total Non Current Assets $9.1M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $89M
Other Current Assets $39M
Other Non Current Assets -
Total Liabilities $155M
Total Current Liabilities $45M
Current Accounts Payable $4.9M
Deferred Revenue -
Current Debt -
Short Term Debt $4M
Total Non Current Liabilities $110M
Capital Lease Obligations $6.3M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $6.3M
Other Current Liabilities $25M
Other Non Current Liabilities -
Total Shareholder Equity $95M
Treasury Stock -
Retained Earnings -$653M
Common Stock $50K
Common Stock Shares Outstanding $50M

yearly Cash Flow (As of Apr 30, 2025)

Field Value (USD)
Operating Cashflow -$153M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $955K
Capital Expenditures $434K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $91M
Cashflow From Financing $160M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$183M

yearly Income Statement (As of Apr 30, 2025)

Field Value (USD)
Gross Profit -$941K
Total Revenue $0
Cost Of Revenue $941K
Costof Goods And Services Sold $941K
Operating Income -$188M
Selling General And Administrative $116M
Research And Development $72M
Operating Expenses $188M
Investment Income Net -
Net Interest Income $650K
Interest Income $6.4M
Interest Expense $5.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $941K
Income Before Tax -$180M
Income Tax Expense $3.4M
Interest And Debt Expense -
Net Income From Continuing Operations -$183M
Comprehensive Income Net Of Tax -
Ebit -$174M
Ebitda -$173M
Net Income -$183M

KALV News

KALV Profile

Kalvista Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

KalVista Pharmaceuticals Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing innovative small-molecule protease inhibitors for unmet medical conditions. The company focuses on therapeutic areas such as hereditary angioedema and diabetic macular edema, utilizing its proprietary drug development platform to create targeted treatments. With a strong pipeline of candidates and strategic partnerships, KalVista is well-positioned to make significant contributions to the pharmaceutical industry, striving to enhance patient outcomes through its commitment to scientific advancement.

VHAI
-20.00%
$0.00
VIVK
+4.67%
$0.30
YYAI
-10.71%
$0.12
BURU
+2.88%
$0.34
NVDA
-0.11%
$179.83
RXRX
-7.21%
$6.29
EPWK
+16.29%
$0.08
CGBS
-39.47%
$0.03
IVF
+153.11%
$1.90
PLUG
-8.70%
$3.51
BITF
-15.68%
$5.45
ADAP
+6.57%
$0.19
YDKG
-54.14%
$0.08
NVTS
+2.73%
$15.57
BYND
-22.39%
$0.52
DNN
-2.83%
$3.08
RGTI
-12.76%
$49.15
NIO
-1.09%
$6.74
MIRA
+49.24%
$1.97
SCNX
-20.41%
$0.56
BBD
+1.71%
$3.25
WHWK
+27.64%
$2.68
F
-0.63%
$11.68
ACHR
-7.36%
$12.07
TLRY
-8.41%
$1.53
TSLA
+1.37%
$435.15
IONZ
+18.46%
$3.41
KVUE
-12.91%
$14.16
AXDX
-61.36%
$0.03
INTC
-1.10%
$36.74
DFLI
-32.52%
$1.32
CAN
-14.28%
$1.68
HPE
-10.09%
$22.51
ONDS
-15.03%
$8.07
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
GDXD
-7.91%
$0.61
ETHD
+4.23%
$3.94
RIG
-3.00%
$3.21
MARA
-11.62%
$20.18
CLF
-3.39%
$13.47
BTG
+3.96%
$5.89
LAES
-15.15%
$6.35
BTBT
-8.99%
$3.69
AAL
-6.00%
$11.75
VSEE
-8.84%
$0.54
GNPX
-47.58%
$0.44
ABAT
-21.00%
$8.94
LGCB
+35.15%
$2.23
QBTS
-10.47%
$40.08
NAK
-14.20%
$2.26
QS
-12.89%
$15.54
QSI
-3.23%
$2.54
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
CRML
-13.96%
$19.54
UUUU
-12.80%
$21.79
QUBT
-12.12%
$18.65
MASK
+18.73%
$0.57
IREN
-8.94%
$61.89
SNAP
-2.46%
$7.71
RR
-6.38%
$5.76
CIFR
-10.08%
$18.91
CLSK
-13.92%
$19.97
FEMY
+31.43%
$0.72
RMBL
+60.50%
$3.21
GPUS
-6.53%
$0.36
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
SOUN
-3.66%
$20.61
WOK
+1.03%
$0.05
AUUD
+3.41%
$2.12
WULF
-9.53%
$13.99
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
APLD
-1.69%
$37.11
NEHC
+9.12%
$3.35
PFE
-0.59%
$24.24
SRM
+53.27%
$10.30
SOND
+78.80%
$1.64
PLTR
-0.81%
$178.16
WTO
-88.69%
$0.13
SMR
-7.73%
$49.29
TOVX
-47.86%
$0.43
FNB
-8.00%
$14.52
KDLY
+1.29%
$0.79
SLNH
-1.39%
$4.23
JBLU
-4.94%
$4.70
AMC
-2.12%
$2.76
AMZN
-0.81%
$213.82
HIMS
-6.07%
$58.94
NOK
+0.44%
$5.67
HBAN
-4.62%
$15.46
SATL
-27.65%
$2.99
ELWS
+48.09%
$5.45
GGB
-0.46%
$3.24
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
-6.45%
$16.58
AG
+2.27%
$15.20
VHAI
-20.00%
$0.00
VIVK
+4.67%
$0.30
YYAI
-10.71%
$0.12
BURU
+2.88%
$0.34
NVDA
-0.11%
$179.83
RXRX
-7.21%
$6.29
EPWK
+16.29%
$0.08
CGBS
-39.47%
$0.03
IVF
+153.11%
$1.90
PLUG
-8.70%
$3.51
BITF
-15.68%
$5.45
ADAP
+6.57%
$0.19
YDKG
-54.14%
$0.08
NVTS
+2.73%
$15.57
BYND
-22.39%
$0.52
DNN
-2.83%
$3.08
RGTI
-12.76%
$49.15
NIO
-1.09%
$6.74
MIRA
+49.24%
$1.97
SCNX
-20.41%
$0.56
BBD
+1.71%
$3.25
WHWK
+27.64%
$2.68
F
-0.63%
$11.68
ACHR
-7.36%
$12.07
TLRY
-8.41%
$1.53
TSLA
+1.37%
$435.15
IONZ
+18.46%
$3.41
KVUE
-12.91%
$14.16
AXDX
-61.36%
$0.03
INTC
-1.10%
$36.74
DFLI
-32.52%
$1.32
CAN
-14.28%
$1.68
HPE
-10.09%
$22.51
ONDS
-15.03%
$8.07
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
GDXD
-7.91%
$0.61
ETHD
+4.23%
$3.94
RIG
-3.00%
$3.21
MARA
-11.62%
$20.18
CLF
-3.39%
$13.47
BTG
+3.96%
$5.89
LAES
-15.15%
$6.35
BTBT
-8.99%
$3.69
AAL
-6.00%
$11.75
VSEE
-8.84%
$0.54
GNPX
-47.58%
$0.44
ABAT
-21.00%
$8.94
LGCB
+35.15%
$2.23
QBTS
-10.47%
$40.08
NAK
-14.20%
$2.26
QS
-12.89%
$15.54
QSI
-3.23%
$2.54
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
CRML
-13.96%
$19.54
UUUU
-12.80%
$21.79
QUBT
-12.12%
$18.65
MASK
+18.73%
$0.57
IREN
-8.94%
$61.89
SNAP
-2.46%
$7.71
RR
-6.38%
$5.76
CIFR
-10.08%
$18.91
CLSK
-13.92%
$19.97
FEMY
+31.43%
$0.72
RMBL
+60.50%
$3.21
GPUS
-6.53%
$0.36
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
SOUN
-3.66%
$20.61
WOK
+1.03%
$0.05
AUUD
+3.41%
$2.12
WULF
-9.53%
$13.99
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
APLD
-1.69%
$37.11
NEHC
+9.12%
$3.35
PFE
-0.59%
$24.24
SRM
+53.27%
$10.30
SOND
+78.80%
$1.64
PLTR
-0.81%
$178.16
WTO
-88.69%
$0.13
SMR
-7.73%
$49.29
TOVX
-47.86%
$0.43
FNB
-8.00%
$14.52
KDLY
+1.29%
$0.79
SLNH
-1.39%
$4.23
JBLU
-4.94%
$4.70
AMC
-2.12%
$2.76
AMZN
-0.81%
$213.82
HIMS
-6.07%
$58.94
NOK
+0.44%
$5.67
HBAN
-4.62%
$15.46
SATL
-27.65%
$2.99
ELWS
+48.09%
$5.45
GGB
-0.46%
$3.24
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
-6.45%
$16.58
AG
+2.27%
$15.20

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.